

INFORMATION DISCLOSURE STATEMENT

Applicant : Weiner et al.
App. No : 10/761,787
Filed : January 21, 2004
For : USE OF N-DESMETHYLCLOZAPINE
TO TREAT HUMAN
NEUROPSYCHIATRIC DISEASE
Examiner : Jennifer M. Kim
Art Unit : 1617

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 8 references to be considered by the Examiner. Also enclosed are 3 non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,
KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 12-13-07

By: Ryan E. Melnick

Ryan E. Melnick
Registration No. 58,621
Attorney of Record
Customer No. 20,995
(619) 235-8550